Glass House, America’s Largest Cannabis Grower by Canopy, Rings the NYSE Bell

Glass House Brands (NYSE: GLAS) rang the Closing Bell at the New York Stock Exchange on Friday, marking the latest milestone in a restructuring that took the California cannabis producer from the OTC market to one of the world’s largest securities exchanges.

Co-Founder, Chairman and CEO Kyle Kazan rang the bell on August 28, nearly two months after Glass House began trading on the NYSE under the ticker GLAS on June 30.

The ceremony itself was symbolic. The road that brought Glass House to the NYSE was anything but.

Glass House spent the months following the federal rescheduling of medical cannabis to Schedule III reorganizing parts of its business around what management sees as a new federal framework for cannabis. That included registering cultivation and processing operations with the Drug Enforcement Administration, converting licenses to medical use, adapting to international standards, and restructuring its retail operations.

Another U.S. cannabis operator has gained access to a major American exchange after years in which federal prohibition largely kept plant-touching companies out.

How Glass House Got to the NYSE

The decisive move came in June.

On June 12, Glass House completed a deconsolidation transaction that separated its California dual-use retail dispensary business from its cultivation, manufacturing, and other operations. Five days later, the company announced that it had applied to list its subordinate voting shares on the NYSE.

Under the restructuring, an independent third-party investor obtained the voting Class A units of Glass House Retail and the right to appoint two of its three managers. Glass House retained non-voting exchangeable units representing roughly 90% of the retail entity’s economic interest on an as-converted basis.

The company explicitly said the transaction segregated its dual-use cannabis business from its medical cannabis operations and facilitated its NYSE application.

Approval came quickly. On June 25, Glass House announced that its shares had been approved for listing. Trading under GLAS began June 30, replacing the company’s previous OTCQX listing in the United States.

The change also expanded Glass House’s financing options. In July, it updated an at-the-market equity program allowing it to sell up to $100 million in shares into both the U.S. and Canadian markets following the NYSE listing.

Why the Listing Matters

Seth Yakatan, an adviser, investor, and shareholder in Glass House, told IgniteIt that major-exchange listings should be understood as one of several incremental changes beginning to reshape cannabis capital markets.

“I think the movement of companies onto listed exchanges is going to be a positive,” Yakatan said.

He cautioned against treating any single regulatory change as the event that suddenly normalizes cannabis.

“What you’ve seen in cannabis is a series of incremental steps,” Yakatan said. “I don’t think any one is this watershed that we’ve expected.”

For Yakatan, banking reform could ultimately represent a considerably larger capital-markets catalyst because of the institutional and strategic capital it could unlock.

Still, an NYSE listing changes the investability equation. Major exchanges offer cannabis companies exposure to a broader pool of investors, greater liquidity potential and financing mechanisms that have largely remained unavailable to U.S. plant-touching operators.

Glass House is already putting some of that infrastructure in place.

Glass House Is Positioning for a Bigger Market

The NYSE move also fits into a broader strategy built around Glass House’s enormous California cultivation footprint and the possibility that federal reform eventually opens interstate and international medical cannabis commerce.

The company produced a record 245,746 pounds of biomass during the second quarter at a production cost of $122 per pound. Glass House expects roughly 1 million pounds of wholesale cannabis biomass production in 2026.

Yakatan believes that scale could become considerably more valuable if U.S.-grown cannabis can eventually enter international medical markets.

“If you believe that there is a moment that is going to occur where you can take EU GACP flower and make it EU GMP and take it through a DEA license and export it, and we believe that future is certain, there’s no one who’s going to be able to compete against Glass House from a price and a quality perspective globally,” he told IgniteIt.

Glass House is actively preparing for that possibility. In July, it retained former DEA compliance executive Matt Murphy to advise the company on Schedule III compliance related to interstate commerce and medical cannabis exports.

Management has gone further, arguing that the rescheduling of medical cannabis creates a pathway for interstate transactions and exports between appropriately registered operators—an interpretation that will ultimately depend on how federal regulators implement and enforce the new framework.

That makes Friday’s Closing Bell more than a photo opportunity.

Glass House has spent 2026 restructuring its operations, licenses, and capital-markets strategy around a bet that federal cannabis reform will gradually bring the industry closer to conventional U.S. markets.

The NYSE bell was the sound of one part of that bet already paying off.